Mar 11, 2025
Novavax Announces Changes to Board of Directors
Feb 20, 2025
Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights on February 27, 2025
Nov 15, 2024
Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)
Nov 12, 2024
Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights
Nov 11, 2024
U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
Nov 04, 2024
Novavax to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Operational Highlights on November 12, 2024
Oct 16, 2024
Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
Sep 13, 2024
Novavax 2024-2025 Formula COVID-19 Vaccine Available at Major Pharmacies Across the U.S.
Sep 04, 2024
Novavax to Participate in Upcoming September Conferences
Aug 30, 2024
Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.
Aug 08, 2024
Novavax Reports Second Quarter 2024 Financial Results and Operational Highlights
Aug 01, 2024
Novavax to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Operational Highlights on August 8, 2024
May 30, 2024
Novavax to Participate in 2024 Jefferies Global Healthcare Conference
Feb 29, 2024
Novavax to Participate in TD Cowen's 44th Annual Health Care Conference
Feb 28, 2024
Novavax Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Feb 20, 2024
Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights on February 28, 2024
Sep 25, 2020
Endo Announces Fill-Finish Manufacturing and Services Agreement for Novavax COVID-19 Vaccine Candidate
Aug 10, 2020
AGC Biologics Expands Partnership with Novavax
Jul 23, 2020
Novavax and FUJIFILM Diosynth Biotechnologies Initiate Large Scale Manufacturing of COVID-19 Vaccine Candidate
Jun 03, 2020
Novavax Selects AGC Biologics to Manufacture Matrix-M(TM) Adjuvant for Novel COVID-19 Vaccine